These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 34154699)
1. Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer. Park S; Lee C; Ku BM; Kim M; Park WY; Kim NKD; Ahn MJ BMB Rep; 2021 Jul; 54(7):386-391. PubMed ID: 34154699 [TBL] [Abstract][Full Text] [Related]
2. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954 [TBL] [Abstract][Full Text] [Related]
3. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels. Endris V; Buchhalter I; Allgäuer M; Rempel E; Lier A; Volckmar AL; Kirchner M; von Winterfeld M; Leichsenring J; Neumann O; Penzel R; Weichert W; Glimm H; Fröhling S; Winter H; Herth F; Thomas M; Schirmacher P; Budczies J; Stenzinger A Int J Cancer; 2019 May; 144(9):2303-2312. PubMed ID: 30446996 [TBL] [Abstract][Full Text] [Related]
4. Tumor Mutational Burden by Whole-Genome Sequencing in Resected NSCLC of Never Smokers. Ruel LJ; Li Z; Gaudreault N; Henry C; Saavedra Armero V; Boudreau DK; Zhang T; Landi MT; Labbé C; Couture C; Desmeules P; Joubert P; Bossé Y Cancer Epidemiol Biomarkers Prev; 2022 Dec; 31(12):2219-2227. PubMed ID: 36126278 [TBL] [Abstract][Full Text] [Related]
5. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Rizvi H; Sanchez-Vega F; La K; Chatila W; Jonsson P; Halpenny D; Plodkowski A; Long N; Sauter JL; Rekhtman N; Hollmann T; Schalper KA; Gainor JF; Shen R; Ni A; Arbour KC; Merghoub T; Wolchok J; Snyder A; Chaft JE; Kris MG; Rudin CM; Socci ND; Berger MF; Taylor BS; Zehir A; Solit DB; Arcila ME; Ladanyi M; Riely GJ; Schultz N; Hellmann MD J Clin Oncol; 2018 Mar; 36(7):633-641. PubMed ID: 29337640 [TBL] [Abstract][Full Text] [Related]
6. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients. Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031 [TBL] [Abstract][Full Text] [Related]
7. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. Kim HS; Cha H; Kim J; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH Eur J Cancer; 2019 Oct; 120():65-74. PubMed ID: 31493723 [TBL] [Abstract][Full Text] [Related]
8. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer. Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895 [TBL] [Abstract][Full Text] [Related]
9. Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort. Bevins N; Sun S; Gaieb Z; Thorson JA; Murray SS J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217764 [TBL] [Abstract][Full Text] [Related]
10. Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing. Zhang W; Wang R; Fang H; Ma X; Li D; Liu T; Chen Z; Wang K; Hao S; Yu Z; Chang Z; Na C; Wang Y; Bai J; Zhang Y; Chen F; Li M; Chen C; Wei L; Li J; Chang X; Qu S; Yang L; Huang J Clin Transl Med; 2021 May; 11(5):e415. PubMed ID: 34047470 [TBL] [Abstract][Full Text] [Related]
11. Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer. Cai L; Bai H; Duan J; Wang Z; Gao S; Wang D; Wang S; Jiang J; Han J; Tian Y; Zhang X; Ye H; Li M; Huang B; He J; Wang J J Immunother Cancer; 2019 Jul; 7(1):198. PubMed ID: 31349879 [TBL] [Abstract][Full Text] [Related]
13. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388 [TBL] [Abstract][Full Text] [Related]
14. Tumor mutational burden on cytological samples: A pilot study. Pepe F; Pisapia P; Gristina V; Rocco D; Micheli M; Micheli P; Iaccarino A; Tufano R; Gragnano G; Russo G; De Luca C; Sgariglia R; Nacchio M; Girolami I; Eccher A; Russo A; Troncone G; Malapelle U Cancer Cytopathol; 2021 Jun; 129(6):460-467. PubMed ID: 33378102 [TBL] [Abstract][Full Text] [Related]
15. Assessments of tumor mutational burden estimation by targeted panel sequencing: A comprehensive simulation analysis. Li D; Wang D; Johann DJ; Hong H; Xu J Exp Biol Med (Maywood); 2023 Nov; 248(21):1918-1926. PubMed ID: 38062992 [TBL] [Abstract][Full Text] [Related]
16. Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB. Sung MT; Wang YH; Li CF Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563486 [TBL] [Abstract][Full Text] [Related]
17. Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing. Wang HY; Deng L; Li YQ; Zhang X; Long YK; Zhang X; Feng YF; He Y; Tang T; Yang XH; Wang F Cancer Res Treat; 2021 Oct; 53(4):973-982. PubMed ID: 33677848 [TBL] [Abstract][Full Text] [Related]
18. Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC. He Y; Chen L; Zhao L; Dang S; Liu G; Sasada S; Ma PC; van Zandwijk N; Rosell R; Popper HH; Wang H; Jiang M; Guo H; Liu X; Chen S; Zhang X; Xu M; Zhu B; Liu M; Zhou C Theranostics; 2021; 11(14):7092-7109. PubMed ID: 34093873 [No Abstract] [Full Text] [Related]
19. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. Fancello L; Gandini S; Pelicci PG; Mazzarella L J Immunother Cancer; 2019 Jul; 7(1):183. PubMed ID: 31307554 [TBL] [Abstract][Full Text] [Related]
20. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies. Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]